Free Republic 4th Quarter Fundraising Target: $85,000 Receipts & Pledges to-date: $20,470
24%  
Woo hoo!! And the first 24% is in!! Thank you all very much!!

Keyword: wetamd

Brevity: Headers | « Text »
  • Lucentis vs. Avastin: Seeing Eye to Eye?

    03/29/2011 7:40:23 PM PDT · by Kaslin · 3 replies
    Townhall.com ^ | March 29, 2011 | Sally C. Pipes
    Everyone who's ever been on the lookout for a good deal knows that price is one thing, but value is another. Cheaper isn't always better; some things that cost more are worth it. That's especially true when it comes to medical treatment, where "one size fits all" and "cheaper is better" are very bad models. Sure, research studies can effectively answer the question of how the average person will respond to a particular course of treatment. But you can only obtain such an average by measuring individual responses, which vary tremendously. The "best" treatment for a particular patient can't be...
  • Drug approved to combat elderly blindness

    06/30/2006 8:56:45 PM PDT · by neverdem · 13 replies · 1,117+ views
    Seattle Post-Intelligencer ^ | June 30, 2006 | ANDREW BRIDGES
    ASSOCIATED PRESS WASHINGTON -- The first drug shown to significantly improve the vision of patients threatened by a major cause of blindness in the elderly won federal approval Friday. The drug, called Lucentis, treats the wet form of age-related macular degeneration, a disorder where blood vessels behind the retina leak blood and fluid, worsening vision and often causing blindness. An estimated 90 percent of the 1.4 million Americans who have lost their eyesight due to the disorder have the wet form. Lucentis, made by Genentech, Inc., a South San Francisco, Calif., biotechnology company, inhibits the growth of blood vessels when...